Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

269
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
269
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Developing and Validating a Risk Model for Severe Bone Marrow Suppression in Esophageal Cancer Treated with Radiotherapy or Chemoradiotherapy: A Retrospective Cohort Study.

Technology in cancer research & treatment·2026
Same author

Shogaol triggers apoptosis and ferroptosis in Ewing sarcoma by targeting the polo-like kinase 1/nucleophosmin 1 axis.

Free radical biology & medicine·2026
Same author

ELK1 promotes the progress of myeloid leukemia by hindering the differentiation of neutrophils.

Experimental hematology & oncology·2026
Same author

TNFSF10 drives hyperactive immune responses via NLRP3 inflammasome and endoplasmic reticulum stress in autoimmune and inflammatory diseases.

Journal of advanced research·2026
Same author

Clinical Impact of MTAP Rearrangement in Pediatric Acute Lymphoblastic Leukemia: Insights From Whole Transcriptome Analysis.

Pediatric blood & cancer·2025
Same author

Matrix-bound nanovesicles drive the engineering of immunomodulatory meshes for abdominal hernia repair.

Biomaterials advances·2025

Related Experiment Video

Updated: May 22, 2025

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.4K

Basic and applied research progress of TRAIL in hematologic malignancies.

Sidong Zhang1, Rongqun Guo2, Yufeng Liu1

  • 1Department of Pediatric Hematology-Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Blood Science (Baltimore, Md.)
|March 14, 2025
PubMed
Summary

This review explores Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) for blood cancers. It discusses TRAIL

Keywords:
Clinical applicationDrug toleranceHematologic malignanciesTRAIL

More Related Videos

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

874
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

Related Experiment Videos

Last Updated: May 22, 2025

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.4K
Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

874
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

Area of Science:

  • Hematology
  • Cancer Biology
  • Immunology

Background:

  • Hematological malignancies are diverse blood cancers with ongoing challenges like relapse and resistance.
  • The World Health Organization classification aids cancer biology understanding and genetic research.
  • Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) shows promise for inducing cancer cell death.

Purpose of the Study:

  • To review TRAIL mechanisms in hematological malignancies.
  • To identify factors contributing to TRAIL resistance.
  • To highlight strategies for enhancing TRAIL-based therapies in blood cancers.

Main Methods:

  • Literature review of preclinical and clinical research on TRAIL in hematological malignancies.
  • Analysis of TRAIL signaling pathways and resistance mechanisms.
  • Examination of current therapeutic strategies and future directions.

Main Results:

  • TRAIL induces apoptosis in cancer cells but faces limitations due to tumor heterogeneity and resistance.
  • Understanding TRAIL resistance mechanisms is crucial for effective treatment.
  • Various strategies are being investigated to overcome TRAIL resistance.

Conclusions:

  • TRAIL remains a promising therapeutic target for hematological malignancies.
  • Overcoming resistance is key to realizing TRAIL's full clinical potential.
  • Further research is needed to optimize TRAIL-based therapies for improved patient outcomes.